Effects of concomitant use of abiraterone and/or enzalutamide with radium-223 on safety and overall survival in metastatic castration-resistant prostate cancer (mCRPC) patients treated in an international early access program (EAP)

被引：5
|
作者：
O'Sullivan, J. [1 ,2 ]
Gillessen, S. [3 ]
Heidenreich, A. [4 ]
Heinrich, D. [5 ]
Gratt, J. [6 ]
Levy, J. [7 ]
Miller, K. [8 ]
Nilsson, S. [9 ]
Saad, F. [10 ]
Tucci, M. [11 ]
Wirth, M. [12 ]
Carles, J. [13 ]
机构：
[1] Queens Univ Belfast, Ctr Canc Res & Cell Biol, Belfast, Antrim, North Ireland
[2] Northern Ireland Canc Ctr, Belfast, Antrim, North Ireland
[3] Kantonsspital, Dept Hematol Oncol, St Gallen, Switzerland
[4] Univ Hosp RWTH Aachen, Dept Urol, Aachen, Germany
[5] Akershus Univ Hosp, Dept Oncol, Lorenskog, Norway
[6] Bayer Healthcare Pharmaceut, Stat Analyt Clin Dev 1, Whippany, NJ USA
[7] BIOP, Biometr Practice, Basel, Switzerland
[8] Charite, Dept Urol, D-13353 Berlin, Germany
[9] Karolinska Univ Hosp, Dept Oncol Pathol, Stockholm, Sweden
[10] Univ Montreal, Hosp Ctr, Dept Surg, Montreal, PQ, Canada
[11] San Luigi Hosp, Dept Oncol, Orbassano, Italy
[12] Univ Hosp Carl Gustav Carus, Dept Urol, Dresden, Germany
[13] Vall dHebron Univ Hosp, Vall dHebron Inst Oncol, Dept Oncol, Barcelona, Spain
来源：
EUROPEAN JOURNAL OF CANCER | 2015年 / 51卷
关键词：
D O I：
10.1016/S0959-8049(16)31380-6
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2561
引用
收藏
页码：S497 / S498
页数：2
相关论文
共 50 条
  • [1] Effects of concomitant use of abiraterone and/or enzalutamide with radium-223 on safety and overall survival in metastatic castration resistant prostate cancer (mCRCP) patients treated in an international early access program (EAP)
    Heidenreich, A.
    O'Sullivan, J.
    Gillessen, S.
    Heinrich, D.
    Gratt, J.
    Levy, J.
    Miller, K.
    Nilson, S.
    Saad, F.
    Tucci, M.
    Wirth, M.
    Carles, J.
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 86 - 87
  • [2] Radium-223 in an international early access program (EAP): Effects of concomitant medication on overall survival in metastatic castration-resistant prostate cancer (mCRCP) patients
    Wirth, M.
    Saad, F.
    Gakeran, J. C.
    Gillessen, S.
    Heinrich, D.
    Graft, J.
    Miller, K.
    Nilsson, S.
    Sullivan, O. J.
    Tucci, M.
    Heidenreich, A.
    Oncology Research and Treatment, 2015, 38 : 266 - 266
  • [3] Radium-223 in an international early access program (EAP): Effects of concomitant medication on overall survival in metastatic castration-resistant prostate cancer (mCRCP) patients.
    Saad, Fred
    Carles, Joan
    Gillessen, Silke
    Heinrich, Daniel
    Gratt, Jeremy
    Miller, Kurt
    Nilsson, Sten
    O'Sullivan, Joe
    Tucci, Marcello
    Wirth, Manfred
    Heidenreich, Axel
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [4] Changes in alkaline phosphatase (ALP) dynamics and overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC) patients treated with radium-223 in an international early access program (EAP)
    Heinrich, D.
    Gillessen, S.
    Heidenreich, A.
    Keizman, D.
    O'Sullivan, J. M.
    Carles, J.
    Wirth, M.
    Miller, K.
    Procopio, G.
    Gratt, J.
    Seger-Van Tol, M.
    Nilsson, S.
    Saad, F.
    ANNALS OF ONCOLOGY, 2016, 27
  • [5] Changes in alkaline phosphatase (ALP) dynamics and overall survival (OS)in metastatic castration-resistant prostate cancer (mCRPC) patients treated with radium-223 in an international early access program (EAP)
    Procopio, G.
    Paganelli, G.
    Cabria, M.
    Cortesi, E.
    Tucci, M.
    Farnesi, A.
    Mango, L.
    Baldari, S.
    Hamzaj, A.
    Caffo, O.
    Marchetti, P.
    Pozza, F. Dalla
    Zucali, P.
    Barsanti, R.
    Heinrich, D.
    ANNALS OF ONCOLOGY, 2017, 28
  • [6] Radium-223 (Ra-223) in asymptomatic metastatic castration-resistant prostate cancer (mCRPC) patients treated in an international early access program (iEAP).
    Heidenreich, Axel
    Gillessen, Silke
    Heinrich, Daniel
    Keizman, Daniel
    O'Sullivan, Joe M.
    Carles, Joan
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [7] Radium-223 with concomitant bone-targeting agents in metastatic castration-resistant prostate cancer (CRPC) patients treated in an international early access program (EAP)
    Paganelli, G.
    Procopio, G.
    Cabria, M.
    Cortesi, E.
    Tucci, M.
    Farnesi, A.
    Mango, L.
    Baldari, S.
    Hamzaj, A.
    Caffo, O.
    Marchetti, P.
    Pozza, F. Dalla
    Zucali, P.
    Barsanti, R.
    Saad, F.
    ANNALS OF ONCOLOGY, 2017, 28
  • [8] Radium-223 with concomitant bone-targeting agents in metastatic castration-resistant prostate cancer (CRPC) patients treated in an international early access program (EAP)
    Saad, F.
    Heidenreich, A.
    Heinrich, D.
    Keizman, D.
    O'Sullivan, J. M.
    Carles, J.
    Wirth, M.
    Miller, K.
    Gratt, J.
    Seger-Van Tol, M.
    Nilsson, S.
    Gillessen, S.
    ANNALS OF ONCOLOGY, 2016, 27
  • [9] Radium-223 (Ra-223) in sequence or in concurrent use with abiraterone acetate (AA) or enzalutamide (E) in metastatic castration resistant prostate cancer (mCRPC) patients treated in an international early access program (iEAP)
    Zastrow, S.
    Saad, F.
    Heinrich, D.
    Gillessen, S.
    OSullivan, J.
    Carles, J.
    Miller, K.
    Huang, L.
    Van Tol, Seeger M.
    Nilsson, S.
    Heidenreich, A.
    ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 : 94 - 94
  • [10] Overall survival prediction in metastatic castration-resistant prostate cancer treated with radium-223
    Vidal, Monica
    Delgado, Alejandro
    Martinez, Carlos
    Jaime Correa, Jose
    Cristina Durango, Isabel
    INTERNATIONAL BRAZ J UROL, 2020, 46 (04): : 599 - 611
12345